Key result
A new, rapid, and precise HPLC method for quantifying doxorubicin in plasma was successfully developed and applied to evaluate the pharmacokinetics of doxorubicin in two pediatric patients with osteosarcoma.
Why the study?
Given known risk factors and multiple cytotoxic mechanisms of doxorubicin, improved and easily usable plasma quantification methods were needed to optimize treatment in pediatric patients.
A new, rapid, and precise HPLC method for quantifying doxorubicin in plasma was successfully developed and applied to study pharmacokinetics in pediatric osteosarcoma patients.
Answers are grounded in this paper and cite their sources.
Enables precise doxorubicin PK monitoring in pediatric osteosarcoma; leaves open clinical adoption pending larger validation studies.
Doxorubicin (Dox) is a drug widely used in cancer chemotherapy. Dox is essential in the treatment of pediatric patients diagnosed with different types of cancer, including osteosarcoma (OS). Dox has been used clinically for more than 3 decades, but recently it has been recognized that the cytotoxic effect occurs by multiple mechanisms that have not yet been conclusively identified. Known risk factors for Dox include cumulative dose, younger age, concomitant use of some other antineoplastic agents, female gender, and increased dose intensity. For these reasons, it is important to develop and improve plasma quantification methods for this antineoplastic drug, with the idea that they are more easily usable in clinical practice and thus seek to improve the treatment of patients using Dox. The objective of the present study was to develop an economical, precise, rapid, and exact analytical method by HPLC for the determination of Dox for pharmacokinetic studies in pediatric patients. This method was successfully applied to study Dox chronopharmacokinetics in pediatric patients with osteosarcoma and thus evaluate its chronotoxicity.
No takes yet. Share an insight, caveat, or question.
Gándara-Mireles et al. (2022) studied Osteosarcoma (n=2). Doxorubicin was evaluated on Pharmacokinetic parameters and HPLC method validation (precision, accuracy, retention time). A new, rapid, and precise HPLC method for quantifying doxorubicin in plasma was successfully developed and applied to evaluate the pharmacokinetics of doxorubicin in two pediatric patients with osteosarcoma.
Synapse has enriched 10 related papers. Consider them for comparative context: